Meta Category: Healthcare

Key Highlights

  • The prospective multicentre trial enrolled 143 patients across 10 US sites.
  • Complete wound closure within 12 weeks occurred in 55% of Symphony-plus-standard-care patients versus 35% with standard care alone.
  • Mean time to complete closure was 65.4 days with Symphony compared with 73.2 days in the control arm.
  • The study evaluated Wagner grade 1 and 2 diabetic foot ulcers.

Aroa Biosurgery Limited (ASX:ARX) has reported randomised controlled trial data showing a higher rate of complete diabetic foot ulcer closure when Symphony was added to standard care. The prospective study enrolled 143 patients at 10 US sites and compared weekly Symphony treatment plus standard care with standard care alone. The findings add controlled clinical evidence to Aroa’s commercial and reimbursement case for Symphony in a difficult wound category.

Twelve-Week Closure Rate Separates the Groups

Within 12 weeks, 55% of diabetic foot ulcers in the Symphony arm achieved complete wound closure compared with 35% in the standard-care-only group. The difference reached statistical significance at p=0.039. Patients enrolled with Wagner grade 1 or 2 ulcers, spanning full-thickness skin wounds through deeper ulcers involving structures such as ligaments, tendons, joint capsules or deep fascia.

Healing Time Also Moves Lower

Mean time to complete closure was 65.4 days for ulcers treated with Symphony plus standard care, versus 73.2 days for the control group. That represents a 7.8-day reduction, with a reported p-value of 0.041. The trial design used random allocation and multiple US sites, giving Aroa a comparative dataset rather than an uncontrolled observational series.

Symphony Sits in the CAMP Market

Symphony is Aroa’s Cellular, Acellular and Matrix-like Product, commonly referred to as a skin substitute. The product combines an extracellular matrix bioscaffold with high-molecular-weight hyaluronic acid. Aroa expects the published trial to support differentiation, clinical adoption and evolving US reimbursement requirements, where comparative evidence is increasingly relevant.

Evidence Does Not Remove Commercial Risk

Positive trial endpoints can support physician and payer discussions, but adoption also depends on reimbursement policy, clinical workflows, sales execution and competition from other wound-care products. The study population and protocol define the evidence generated, so real-world uptake will still need to be demonstrated through commercial performance.

Forward-Looking Summary

Aroa can now use the published randomised data in clinical and reimbursement discussions while monitoring how the evidence translates into Symphony adoption across US wound-care settings.